Surrozen to Spotlight Novel Ophthalmic Therapies at Key Investor Summit

SOUTH SAN FRANCISCO, CA – February 05, 2026 – Biotechnology firm Surrozen, Inc. (Nasdaq: SRZN) is preparing to take the stage at the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 12, where company management will detail its ambitious strategy to treat sight-threatening eye diseases. The presentation offers a critical opportunity for the company to articulate its vision to investors following a significant strategic pivot and a major financing round designed to fuel its innovative pipeline.

Surrozen is pioneering therapeutics based on Wnt signaling, a fundamental biological pathway crucial for tissue development and repair that has long been considered a challenging target for drug development. The company's participation in the high-profile investor conference signals its intent to solidify its position as a leader in this nascent field and attract the long-term capital necessary to bring its potentially revolutionary treatments to patients.

A Decisive Pivot to Ophthalmology

Surrozen's upcoming presentation comes on the heels of a transformative period for the company. In a decisive strategic shift, the firm has focused its entire research and development engine on ophthalmology, discontinuing its former lead program, SZN-043, which was being investigated for severe alcohol-associated hepatitis. The company cited insufficient early clinical benefit for the discontinuation, choosing instead to concentrate resources on what it sees as a more promising application of its technology: tackling severe eye diseases.

This pivot has been backed by a significant infusion of capital. Surrozen recently secured $175 million in gross proceeds from a private placement financing, with an initial tranche of approximately $76.4 million received in March 2025. This funding has substantially bolstered the company's balance sheet, with cash and cash equivalents rising to $81.3 million as of September 30, 2025, from $34.6 million at the end of 2024. The capital is earmarked to advance multiple ophthalmology programs through Phase 1 clinical studies, a critical stage in proving a drug's safety and initial efficacy.

However, the high-cost nature of biotechnology is evident in the company's financial statements. Surrozen continues to operate at a significant net loss, which stood at $71.6 million for the third quarter of 2025. This underscores the high-stakes environment for clinical-stage biotechs, where investor confidence and consistent funding are paramount to navigating the lengthy and expensive path to commercialization.

The Science of Sight: Unlocking the Wnt Pathway

At the core of Surrozen's investor pitch is its proprietary antibody-engineering platform designed to harness the power of Wnt signaling. This pathway plays a vital role in tissue regeneration, but its complexity has made it notoriously difficult to target therapeutically. Surrozen believes it has cracked the code with its Surrozen Wnt Signal Activating Proteins (SWAPs), which are designed to selectively activate the pathway in diseased tissues.

The company's ophthalmic pipeline features several multi-functional candidates that aim to not only compete with but improve upon the current standard of care for major retinal diseases.

• SZN-8141: This bifunctional antibody is a cornerstone of the new strategy. It combines targeted Wnt agonism via the Frizzled 4 (FZD4) receptor with the inhibition of Vascular Endothelial Growth Factor (VEGF). Anti-VEGF therapies are the current multi-billion dollar standard for conditions like wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). By adding the regenerative potential of Wnt activation, Surrozen hopes to offer a more durable and effective treatment. The company is on track to submit an Investigational New Drug (IND) application for SZN-8141 in 2026.

• SZN-8143: Taking the multi-functional approach a step further, this trifunctional antibody adds Interleukin-6 (IL-6) inhibition to the Wnt agonism and VEGF blockade. By targeting inflammation alongside vascular leakage and tissue repair, SZN-8143 could be a powerful option for complex conditions like DME, AMD, and uveitic macular edema.

• SZN-413: Licensed to pharmaceutical giant Boehringer Ingelheim, this bispecific Wnt agonist has shown preclinical promise in reversing retinopathy by restoring healthy blood vessel function. The partnership lends significant external validation to Surrozen's platform.

This approach of creating single-molecule therapies with multiple mechanisms of action represents a key trend in modern drug development, aiming to provide superior outcomes by addressing the complex, multifactorial nature of diseases like those affecting the eye.

High Hopes Meet Financial Realities

For investors tuning into the Guggenheim webcast, the key question will be how this promising science translates into a viable business. Analyst coverage reflects this high-risk, high-reward dynamic. Wall Street has generally assigned "Buy" or "Outperform" ratings to SRZN stock, with price targets suggesting significant upside. For instance, H.C. Wainwright has reiterated a "Buy" rating with a $32 price target, and LifeSci Capital initiated coverage with an "Outperform" rating and a $36 target.

Despite the optimism, profitability remains a distant prospect, and some metrics, like a recent increase in short interest, suggest a degree of investor skepticism. Much is riding on the company's execution of its clinical development plan. A crucial milestone for Surrozen is the planned IND submission for SZN-8141. Notably, the second tranche of its $175 million financing is contingent upon the FDA's clearance of this application, making it a critical catalyst for the company's near-term financial stability and its ability to fund further trials.

The Guggenheim presentation will be management's platform to reassure investors that its strategy is sound, its pipeline is progressing, and its technology holds the potential to disrupt the estimated $15 billion anti-VEGF market. They will need to make a compelling case that their Wnt-based therapies can offer a regenerative and more durable alternative to existing treatments, addressing the significant unmet need for therapies that can preserve and potentially restore vision for millions of patients worldwide.